May 1, 2025
Clients have asked Brandon Shirley about acquiring a health entity that would qualify for the 340B Drug Pricing Program because, as he explains, “it does enable substantial benefits if you can get into it.” But the program is also complex. A healthcare Senior Associate at Krieg DeVault, Brandon dissects 340B, which requires drug manufacturers to provide upfront discounts to eligible healthcare entities serving uninsured and low-income populations. With host George Lepeniotis, he clarifies who qualifies as a "covered entity," explains the disputes over patient eligibility definitions, and addresses the controversial manufacturer-proposed "rebate model".
Disclaimer: The contents of this article should not be construed as legal advice or a legal opinion on any specific facts or circumstances. The contents are intended for general informational purposes only, and you are urged to consult with counsel concerning your situation and specific legal questions you may have.
Practices
Industries
May 1, 2025
Clients have asked Brandon Shirley about acquiring a health entity that would qualify for the 340B Drug Pricing Program because, as he explains, “it does enable substantial benefits if you can get into it.” But the program is also complex. A healthcare Senior Associate at Krieg DeVault, Brandon dissects 340B, which requires drug manufacturers to provide upfront discounts to eligible healthcare entities serving uninsured and low-income populations. With host George Lepeniotis, he clarifies who qualifies as a "covered entity," explains the disputes over patient eligibility definitions, and addresses the controversial manufacturer-proposed "rebate model".
Disclaimer: The contents of this article should not be construed as legal advice or a legal opinion on any specific facts or circumstances. The contents are intended for general informational purposes only, and you are urged to consult with counsel concerning your situation and specific legal questions you may have.